

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 February 2003 (13.02.2003)

PCT

(10) International Publication Number
WO 03/012100 A2

- (51) International Patent Classification⁷: **C12N 15/10**, (74) Agents: **HELBING, Jörg** et al.; Von Kreisler Selting
C12Q 1/68 Werner, Postfach 10 22 41, 50462 Köln (DE).
- (21) International Application Number: **PCT/EP02/08122** (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
(22) International Filing Date: **20 July 2002 (20.07.2002)** CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
(25) Filing Language: **English** LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
(26) Publication Language: **English** SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.
- (30) Priority Data: 01118416.5 31 July 2001 (31.07.2001) EP (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, ÜG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **DIREVO
BIOTECH AG** [DE/DE]; Nattermannallee 1, 50829 Köln
(DE):
- (72) Inventors; and
(75) Inventors/Applicants (*for US only*): **KOLTERMANN,
Andre** [DE/DE]; c/o Direvo Biotech AG, Nattermannallee
1, 50829 Köln (DE). **KETTLING, Ulrich** [DE/DE]; c/o
Direvo Biotech AG, Nattermannallee 1, 50829 Köln (DE).
GREINER-STÖFFELE, Thomas [DE/DE]; Untere Eich-
stadtstrasse 22, 04299 Leipzig (DE). **SPANGENBERG,
Oliver** [DE/DE]; c/o DIREVO BIOTECH AG, Natterman-
allee 1, 50829 Köln (DE).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED
PARTS OF SOURCE NUCLEIC ACIDS**

(57) Abstract: The present invention relates to a method for the production of nucleic acids consisting of stochastically combined
parts of source nucleic acids as well as to a kit containing instructions for carrying out said method

WO 03/012100 A2

Method for the Production of Nucleic Acids Consisting of Stochastically Combined Parts of Source Nucleic Acids

The present invention relates to a method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids as well as to a kit for carrying out said method.

In nature, nucleic acids provide the biological information that determines structure and function of proteins and, thereby, controls the entire functionality of living beings, from the simplest bacterial cell to very complex multi-cellular organisms. It has been shown, that proteins can be engineered to have new or altered properties that can be exploited for technical or medical purposes. Such engineering can be done by modifying the nucleic acid sequence coding for the corresponding protein, expressing the protein by means of an expression system, testing the protein properties by a sufficiently powerful screening technique and selecting those that are best performers. Of course, when nucleic acids serve as functional molecules themselves, this procedure can be employed as well. Whenever the procedure is done in an iterative manner, the technique is termed directed evolution by analogy to nature's way to generate new functions and alter existing ones.

The modification of nucleic acids is an intrinsic step in directed evolution. Besides the introduction of punctual mutations, the recombination of sequence parts is a very successful strategy for modifying nucleic acids and for generating diverse libraries that can be subjected to screening and selection procedures afterwards. Sequence parts may be fragments of a genome, gene clusters, genes variants within a gene cluster, parts of genes such as exons, or sequences coding for domains within a protein, but may also be very short nucleic acid fragments down to few or even single nucleobases.

Recombination of parts of nucleic acids is preferably done by homologous recombination. Homologous recombination is the combination of corresponding se-

and reading frame. Main advantage of homologous recombination is the prevention of background noise of unrelated sequences that accompanies an unspecific recombination.

Experimentally, homologous recombination is preferably done *in vitro* using individual enzymatic functions or defined mixtures or sequences of enzymatic processing steps.

A first *in vitro* method described in WO 95/22625 is PCR-based (see also Stemmer, Nature 370 (1994) 389). Here, overlapping gene fragments are provided and are subsequently assembled into products of original length by a PCR without addition of primers. Thus, the mutual priming of the fragments in each PCR cycle allows for fragments of different origin to be incidentally linked to form a product molecule. Theoretically, recombination events introduced by this method are stochastically distributed over the whole resulting nucleic acid sequence. The number of recombination events per nucleic acid molecule, i.e. the frequency of recombination, and also the average distance between recombination sites is determined by the fragment length. On the other hand, the minimal fragment size is in the order of hundreds of base pairs in order to enable mutual priming at a sufficient rate. The shorter the fragments the lower is the probability of efficient annealing of fragments. Therefore, the number of recombination events per gene is limited and, moreover, the minimal average distance of recombination sites is restricted. No means is provided to control these factors.

Another PCR-based method is described in WO 98/42728 (Shao et al., Nucl. Acids Res. 26 (1998), 681). Here, primers with randomized sequences are used which enable a start of polymerization at random positions within a polynucleotide. Thus, similar to WO 95/22625, short polynucleotide fragments are formed which can recombine with each other by mutual priming. With this method, controlling the frequency and distance of the recombinations is hardly possible. Moreover, unspecific primers lead to a comparatively high inherent error rate which can constitute a problem with sensitive sequence parts and/or long genes.

Another method described in WO 98/42728 uses a modified PCR protocol to promote strand exchange during the primer extension step in PCR (Zhao et al.

Nat. Biotechnol. 16 (1998), 258). The method consists of priming template sequences with a primer followed by repeated cycles of denaturation and extremely abbreviated annealing and polymerase-catalyzed extension. In each cycle the growing fragments can anneal to different templates based on sequence complementarity and extend further. This is repeated until full-length sequences form. Due to template switching, resulting polynucleotides can contain sequence information from different parental sequences. Accordingly, the recombination frequency is controlled by the number of PCR cycles while the average distance between recombination sites is determined by the actual setting of the polymerization time. Due to technical limitations of provoking fast temperature shifts, the minimal average distance between recombination sites is in the range of hundred nucleobases.

WO 01/34835 describes a method for homologous recombination that is not PCR-based. This method combines the controllability of the recombination frequency with the possibility of regio-selective recombination. The method employs partial exonucleolytic single-strand degradation and template-directed single-strand synthesis of double-stranded heteroduplexes that are formed by melting and re-annealing of source nucleic acids. Multiple recombinations are achieved by repeating the degradation and re-synthesis steps in an iterative manner. Accordingly, the number of cycles determines the recombination frequency. By controlling the exonucleolytic activity, the method allows for regioselective recombination. Very short distances between recombination sites are practically only achieved when focusing on a certain region in the range of hundred nucleobases in the source nucleic acid molecules. Short average distances over the entire source nucleic acid sequences are difficult to achieve.

Another method for homologous recombination that is not PCR-based is described in WO 01/29211. The method relies on the ordering, trimming and joining of randomly cleaved parental DNA fragments annealed to a transient polynucleotide scaffold. As for WO 95/22625, the minimal length of the generated fragments is limited by the necessity of an efficient annealing to the template. Therefore, the minimal distance between recombination sites is not below several hundred nucleobases.

Thus, the technical problem underlying the present invention is to provide a method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids. Especially, the technical problem is to provide an *in vitro* homologous recombination method that allows the targeted and defined positioning of recombination sites. Several directed evolution experiments have shown the necessity of executing homologous recombination in a controlled fashion. For example, recombination of protein modules requires the positioning of recombination sites into a narrow range of the polynucleotide sequence. Recombination of CDRs in an antibody requires the targeting of certain parts of the coding polynucleotide. Current recombination methods lack sufficient controllability with respect to these factors. Therefore, targeting and directing should be possible with regard to the strand that is recombined, to the position in the sequence, and to the average distance between recombination sites. In benefit of this, homologous *in-vitro* recombination would act as precisely as it is required for a number of directed evolution problems in a way that is not achieved by the methods that are currently available.

Summary of the Invention

The technical problem has been solved by providing the embodiments characterized in the claims. The present invention thus provides

(A) a method for the production of polynucleotide molecules with modified properties, comprising the following steps:

- (1) providing a population of source nucleic acid molecules, the individual nucleic acid molecules of said population having homologous and heterologous segments and having at least one marker nucleotide incorporated within its nucleic acid sequence;
- (2) forming double-stranded polynucleotide molecules of the population of source nucleic acid molecules provided according to step (1) comprising double strands with heterologous segments (heteroduplices);
- (3) producing single-stranded breaks at the incorporated marker nucleotides of the double-stranded heteroduplices produced according to step (2); and
- (4) performing template-directed single-strand synthesis, with or without incorporation of marker nucleotides starting from single-stranded breaks

(B) a kit for carrying out the method as defined in (A) above, preferably said kit containing at least one of the following components:

- (i) marker nucleotides for incorporation in the polynucleotide molecules;
- (ii) agents permitting the single-stranded breaks at the incorporated marker nucleotides; and
- (iii) buffers for carrying out the incorporation of the marker nucleotides and producing the single-stranded breaks at these sites.

In the method of embodiment (A) of the invention, in step (1) - if the source nucleic acid molecule is double stranded - the strands may be complementary or partially complementary. Moreover, steps (3)-(4) may be carried out subsequently or contemporaneously. The following figures further explain the embodiments of the invention. The figures are, however, not to be construed to limit the invention.

Short Description of the Figures

- Figure 1: is a schematic illustration of the method of the invention.
- Figure 2: illustrates the principle of the method using dUMP as the marker nucleotide and employing UDG, a class II AP endonuclease and a dRPase for the introduction of single-stranded breaks at the marker nucleotides.
- Figure 3: illustrates the principle of the method using dUMP as the marker nucleotide and employing UDG, a class I AP endonuclease and a class II AP endonuclease for the introduction of single-stranded breaks at the marker nucleotides.
- Figure 4: illustrates the principle of the method using dUMP as the marker nucleotide and employing UDG, Endo VIII or Fpg, and a class II AP endonuclease or a T4 polynucleotide kinase for the introduction of single-stranded breaks at the marker nucleotides.
- Figure 5: illustrates the principle of the method using rNMP as the marker nucleotide and employing RNase H for the introduction of single-stranded breaks at the marker nucleotides.
- Figure 6: is a schematic illustration of the method of the invention employing three cycles.

Figure 7: depicts a plasmid map of the shuttle vector pBV43 used in Example 3 of the Experimental Section, having the subtilisin gene inserted behind the P43 promoter.

Figure 8: shows the mutations found in a representative set of recombinants that was obtained by the method of the invention as described in Example 3. The mutations are defined as differences in the amino acid sequence when comparing the variants with the subtilisin wild type amino acid sequence (SEQ ID NO:5). The amino acids are abbreviated according to the one-letter codes as listed in Table 1. For example, "E160D" means that Glutamic acid (abbreviated as E) at position 160 of the wild type amino acid sequence is replaced by Aspartic acid (abbreviated as D).

Figure 9: shows the results when performing the method of the invention for three rounds with four different variants of the subtilisin gene from *Bacillus subtilis* as described in Example 3. (A) Average number of recombination events per gene; (B) Fraction of recombinants among the resulting population. N is the number of clones in each experiment that was analyzed by sequence analysis. 1:1, 1:3 and 1:9 denote different ratios of the concentration of non-dUTP-containing strands to the concentration of dUTP-containing strands used in the method.

Detailed Description of the Invention

As set forth above, embodiment (A) of the invention relates to a method for the production of nucleic acids with modified properties, i.e., polynucleotides consisting of stochastically combined parts of the source nucleic acids. Said embodiment will be described in more detail with reference to figure 1, which schematically shows a possible variant of the method of the invention.

Depending on the requirements, the method of the invention permits both an incidental and a controlled new combination of heterologous sequence segments. By adjusting the probability of incorporation of marker nucleotides the average distance between recombination sites can be controlled. Distances down to one

nucleotide are possible using appropriate ratios of nucleotides and marker nucleotides. This is hardly achieved with any of the before mentioned methods. In addition, the frequency of recombination can be controlled in a wide range by adjusting the number of cycles and the average recombination distance per cycle. Such a control of the recombination frequency may also be achieved by means of the method described in WO 01/34835 and the method described in WO 98/42728 that relies on a PCR with strand exchange. It is at least in part achieved by means of the methods described in WO 95/22625 and WO 01/29211. The method described in WO 98/42728 that relies on random priming provides no means to control the recombination frequency.

Another aspect of methods for homologous recombination is their requirement for a certain degree of homology between the source nucleic acids to be recombined. The methods described in WO 95/22625, WO 98/42728 and WO 01/29211 all rely on the annealing of short sequence segments between the sites of recombination. In case that recombination events shall be distributed evenly over the entire nucleic acid sequence, this means that the entire source nucleic acid sequences have to provide sufficient homology to enable annealing of short nucleic acid segments. Regions within the nucleic acid sequences with lower homology permit said annealing and accordingly interrupt the recombination reaction. In contrast, the method described in WO 01/34835 as well as the method of the invention employ annealing of full length nucleic acid sequences to produce heteroduplexes which are subjected to the recombination process. Thereby, also regions with rather low homology within the nucleic acid sequence do not interrupt the recombination and an overall lower homology is tolerated when compared to the above mentioned methods.

Hence, the method of the invention is characterized by a combination of advantages which could not be achieved with any of the methods disclosed so far.

Products resulting from each individual cycle according to the method of the invention are semi-conservative, single-stranded nucleic acid molecules, since - depending on the embodiment - a longer or shorter sequence segment was maintained at one side of the marker nucleotide incorporation site while the se-

quence segment on the other side of the marker nucleotide incorporation site was synthesized newly with the information of the template strand.

The term "marker nucleotides" in accordance with the present invention means any nucleic acid monomer that is suited to be incorporated into a polynucleotide and that can be used as a marker to introduce single-stranded breaks at the corresponding position in order to provide intramolecular starting points for a template-directed polymerization reaction. Preferably, marker nucleotides are analogous of standard nucleotides that can be recognized specifically by a chemical reaction or by enzymatic treatment.

In a preferred embodiment, more than one cycle comprising the aforementioned steps (1) to (4) is completed, i.e. at least two, preferably at least ten, more preferably at least twenty and most preferably at least fifty cycles. In this embodiment, the template directed single-strand synthesis in step (4) is done with incorporation of marker nucleotides, thereby introducing in each cycle the marker nucleotides for the next cycle. Then, preferably, the last cycle is done without incorporation of marker nucleotides in order to produce double-strands free from marker nucleotides that can be processed further.

The cyclic application of the method of the invention makes it possible to produce nucleic acid molecules comprising multiple recombined sequence segments from different source nucleic acids. In particular, the cyclic application makes it possible to combine several heterologous sequence segments which each other. Moreover, it is possible to control the recombination frequency for each polynucleotide strand by the number of cycles. With cyclic application, the average distance between the new combinations can be controlled by the probability of incorporating marker nucleotides in each cycle.

In particular, the average distance between the starting points of the template-directed synthesis according to step (4) in each of two consecutive cycles is controlled by adjusting the probability of incorporating marker nucleotides in step (4) of the first of the two consecutive cycles. The probability of incorporating marker nucleotides can be controlled by adjusting the ratio of concentrations of marker nucleotides to standard nucleotides. Preferably, the probability of incorporating

marker nucleotides is chosen to be lower than one and higher than the reciprocal of the length of the source nucleic acids in base pairs. It is noteworthy that, whenever more than one marker nucleotide is incorporated per polynucleotide strand, only the marker nucleotide incorporated next to the starting point of the template-directed polymerization determines the distance between recombination sites. All other marker nucleotides are removed without consequences (cf. Fig. 1).

In a preferred embodiment, the nucleic acid molecules in the population of source nucleic acid molecules provided according to step (1) are double strands and the marker nucleotides are incorporated within the nucleic acid sequence in both strands. Here, both strands are accessible for the production of single-stranded breaks according to step (3) and, therefore, both strands are subjected to recombination and, at the same time, can serve as template strands.

In another preferred embodiment, the nucleic acid molecules in the population of source nucleic acid molecules provided according to step (1) are double strands and the marker nucleotides are incorporated within the nucleic acid sequence in only one of both strands (marker strand or sense strand). Accordingly, only one of both strands is accessible for the production of single-stranded breaks according to step (3) and, therefore, only one of both strands is subject for recombination. The other strand serves only as a template during the whole process (template strand or antisense strand).

In a particularly preferred embodiment, said double strands consisting of a marker strand and a template strand are produced by PCR using one primer having at least one marker nucleotide incorporated and a second primer without having any marker nucleotides incorporated.

In another particularly preferred embodiment, said double strands consisting of a marker strand and a template strand are produced by annealing two single strands, each of which is produced by asymmetric PCR using only one primer, the marker strand being produced with incorporation of marker nucleotides during the polymerization step, while the template strand is produced without incorporation of marker nucleotides during the polymerization step.

In another preferred embodiment, the marker nucleotides incorporated in the population of source nucleic acid molecules provided according to step (1) are incorporated next to the 5'-end and the recombination site defined by the incorporation site of marker nucleotides and the corresponding single-stranded break according to step (3) gets closer to the 3'-end of the polynucleotide molecules with increasing cycle number.

In another preferred embodiment, when more than one cycle is completed, the probability of incorporating marker nucleotides is altered from cycle to cycle. For example, this can be done by altering the ratio of concentrations of marker nucleotides and corresponding standard nucleotides. In this way, the distance between recombination sites can be controlled regioselectively.

The population of source nucleic acid molecules provided according to step (1) of the method of the invention can be any population of nucleic acid molecules comprising at least two kinds of polynucleotides, consisting of homologous and heterologous segments. Preferably, two of these polynucleotides each have at least one homologous and two heterologous sequence segments when compared with each other. The term "population of nucleic acid molecules" refers to any kind of nucleic acid, e.g. single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, double-stranded hybrids of DNA and RNA, or mixtures of any of these. In principle, the method may also be used for similarly constructed, artificial polymers. The term "homologous segments" denotes segments which are identical or complementary on two or more nucleic acid molecules, i.e. which have the same information at corresponding positions. The term "heterologous segments" means segments which are not identical or complementary on two or more nucleic acid molecules, i.e. which have different information at corresponding positions. The term "information" or "genotype" of a nucleic acid molecule is the sequential order of various monomers in a nucleic acid molecule. A heterologous sequence segment has preferably a length of at least one nucleotide, but may also be much longer. For example, a heterologous sequence segment may have a length of two nucleotides or three nucleotides, e.g. a codon. In principle, there is no upper limit as regards the length of the heterologous segment. Nevertheless, the length of a heterologous segment

should not exceed 1,000 nucleotides, preferably it should not be longer than 500 nucleotides, more preferably not longer than 200 nucleotides and most preferably not longer than 100 nucleotides. Such longer sequence segments may, for example, be the hypervariable regions of a sequence encoding an antibody, domains of a protein, genes in a gene cluster, regions of a genome, etc. Preferably, the heterologous segments are sequence segments in which the nucleic acid molecules differ in single bases. Heterologous segments, however, may also be based on the fact that a deletion, duplication, insertion, inversion, addition or similar is present or has occurred in a nucleic acid molecule.

According to the invention, the nucleic acid molecules provided according to step (1) of embodiment (A) have preferably at least one homologous and at least two heterologous sequence segments. More preferably, however, they have a plurality of homologous and heterologous segments. In principle, there is no upper limit to the number of homologous and heterologous segments. A population of source nucleic acid molecules according to the invention may consist of (i) gene variants each carrying one or more point mutations at various positions, or (ii) of gene homologous obtained from different species providing sufficient homology to produce - at least partially - heteroduplexes, or (iii) of gene variants each carrying one or more randomized cassettes such as antibody gene libraries. This enumeration is, however, not to be construed to limit the invention.

The heterologous segments in the population of nucleic acid molecules provided according to step (1) of the method are each interrupted by homologous segments. The homologous segments preferably have a length of at least 5, more preferably of at least 10 and most preferably of at least 20 nucleotides. Like the heterologous segments, the homologous segments, too, may be much longer and, in principle, there is no upper limit to their length. Preferably, their length should not exceed 5,000 nucleotides, more preferably not longer than 2,000 nucleotides and most preferably not longer than 1,000 nucleotides.

In a particularly preferred embodiment of the method of the invention related nucleic acid sequences are used for providing a population of source nucleic acid molecules according to step (1). In this context, the term "related" means polynucleotides which have both homologous and heterologous segments among

each other. Related nucleic acid molecules may originate from a procedure to introduce random point mutations into a source nucleic acid sequence. This introduction of point mutations can be achieved by the inherent erroneous copying process alone, but also by the purposeful increase of the inaccuracy of the polymerase used (e.g. by defined non-balanced addition of the monomers, by addition of base analogues, by error-prone PCR, by polymerases with very high error rate), by chemical modification of polynucleotides after synthesis, by the complete synthesis of polynucleotides under at least partial application of monomer mixtures and/or of nucleotide analogues, by erroneous replication *in vivo* (e.g. by viruses having high error rates, by bacterial mutator strains, by bacteria under UV irradiation, etc.), as well as by a combination of two or more of these methods. Related nucleic acid molecules may also be nucleic acid molecules, that have been subjected to an alternative nucleic acid variation method, such as the random truncation, insertion, deletion or inversion of sequence segments or the introduction of randomized sequence segments. Related nucleic acid molecules may also be nucleic acid sequences of the distribution of mutants of a quasi-species. A "quasi-species" is a dynamic population of related molecule variants (mutants) which is formed by faulty replication and subsequent selection (WO 92/18645). Alternatively, related nucleic acid molecules may be nucleic acid sequences isolated from natural sources that have a sufficient degree of homology to form heteroduplices according to step (2) of the method. For example, analogous genes or gene fragments isolated from genomes of evolutionary related species can be employed. Any of these related nucleic acid molecules may be used directly or be subjected to a screening and/or selection procedure before application of the recombination procedure, the selection and/or screening procedure selecting those nucleic acid molecules that have a certain phenotype. The term "phenotype of a nucleic acid molecule" denotes the sum of functions and properties of the nucleic acid molecule and of the transcription or translation products encoded by the nucleic acid molecule.

The incorporation of marker nucleotides according to step (1) and, where applicable, according to step (4) is achieved by using a template directed polymerase reaction or by chemical synthesis of oligonucleotides. Preferably, the incorporation of marker nucleotides according to step (4) is done by using a template-directed polymerase reaction.

For said template-directed polymerase reaction according to step (4) of the method any enzyme with template directed polynucleotide-polymerization activity can be used which is able to polymerize polynucleotide strands starting from the 3'-end. A vast number of polymerases from the most varied organisms and with different functions have already been isolated and described. With regard to the kind of the template and the synthesized polynucleotide, a differentiation is made between DNA-dependent DNA polymerases, RNA-dependent DNA polymerases (reverse transcriptases), DNA-dependent RNA polymerases and RNA-dependent RNA polymerases (replicases). With regard to temperature stability, a differentiation is made between non-thermostable (37°C) and thermostable polymerases (75-95°C). In addition, polymerases differ with regard to the presence of 5'-3'- and 3'-5'-exonucleolytic activity.

When both, the template strand and the marker strand consist of DNA, DNA-dependent DNA polymerases are preferably used. In particular, DNA polymerases with a temperature optimum of exactly or around 37°C are used. These include, for instance, DNA polymerase I from *E. coli*, T7 DNA polymerase from the bacteriophage T7 and T4 DNA polymerase from the bacteriophage T4 which are each traded by a large number of manufacturers. The DNA polymerase I from *E. coli* (holoenzyme) has a 5'-3' polymerase activity, a 3'-5' proofreading exonuclease activity and a 5'-3' exonuclease activity. The enzyme is used for in vitro labeling of DNA by means of the nick-translation method (J. Mol. Biol. 113 (1977), 237-251). In contrast to the holoenzyme, the Klenow fragment of DNA polymerase I from *E. coli* does not have a 5'-exonuclease activity, just like the T7 DNA polymerase and the T4 DNA polymerase. Therefore, these enzymes are used for so-called filling-in reactions or for the synthesis of long strands (Biochemistry 31 (1992), 8675-8690, Methods Enzymol. 29 (1974), 46-53). The 3'-exo(-) variant of the Klenow fragment of DNA polymerase I from *E. coli* does not have the 3'-exonuclease activity. This enzyme is often used for DNA sequencing according to Sanger (Proc. Natl. Acad. Sci. USA 74 (1977), 5463-5467). Apart from these enzymes, there is a plurality of other 37°C DNA polymerases with different properties which can be employed in the method of the invention.

Moreover, thermostable DNA polymerases can be used for the method of the invention. Preferably, the most widespread thermostable DNA polymerase that has a temperature optimum of 75°C and is still sufficiently stable at 95°C, the Taq DNA polymerase from *Thermus aquaticus*, can be used. Taq DNA polymerase is commercially available from various manufacturers. Taq DNA polymerase is a highly-processive DNA polymerase without 3'-exonuclease activity. It is often used for standard PCRs, for sequencing reactions and for mutagenic PCRs (PCR Methods Appl. 3 (1994), 136-140, Methods Mol. Biol. 23 (1993), 109-114). However, several other thermostable DNA polymerases can be employed. The Tth DNA polymerase from *Thermus thermophilus* HB8 and the Tfi DNA polymerase from *Thermus flavus* have similar properties. The Tth DNA polymerase additionally has an intrinsic reverse transcriptase (RT) activity in the presence of manganese ions (Biotechniques 17 (1994), 1034-1036). Among the thermostable DNA polymerases without 5'- but with 3'-exonuclease activity, numerous of them are commercially available: Pwo DNA polymerase from *Pyrococcus woesei*, Tli, Vent or DeepVent DNA polymerase from *Thermococcus litoralis*, Pfx or Pfu DNA polymerase from *Pyrococcus furiosus*, Tub DNA polymerase from *Thermus ubiquitous*, Tma or UITma DNA polymerase from *Thermotoga maritima*. Polymerases without 3'-proofreading exonuclease activity are used for amplifying PCR products that are as free from defects as possible. With the Stoffel fragment of Taq DNA polymerase, with Vent-(exo-) DNA polymerase and Tsp DNA polymerase thermostable DNA polymerases without 5'- and without 3'-exonucleolytic activity are available.

When RNA is used as the template strand nucleic acid and DNA as the marker strand nucleic acid, RNA-dependent DNA polymerases (reverse transcriptases) can be employed. Among the reverse transcriptases, preferably, the AMV reverse transcriptase from the avian myeloblastosis virus, the M-MuLV reverse transcriptase from the Moloney murine leukemia virus or the HIV reverse transcriptase from the human immunodeficiency virus is used. All three enzymes are traded by various manufacturers. Like the HIV reverse transcriptase, the AMV reverse transcriptase has an associated RNase-H activity. This activity is significantly reduced in M-MuLV reverse transcriptase. Both the M-MuLV and the AMV reverse transcriptase do not have a 3'-exonuclease activity. Furthermore, a

from *Thermus thermophilus* with intrinsic reverse transcriptase activity is particularly preferred.

When DNA is used as the template strand nucleic acid and RNA as the marker strand nucleic acid, DNA-dependent RNA polymerases may be employed. Preferably, the RNA polymerase from *E. coli*, the SP6-RNA polymerase from *Salmonella typhimurium* LT2 infected with the bacteriophage SP6, the T3-RNA polymerase from the bacteriophage T3 or the T7-RNA polymerase T7 from the bacteriophage T7 is used.

In a preferred embodiment of the method, DNA is used as nucleic acid and deoxyuridine triphosphate (dUTP) is used as the marker nucleotide. Here, the incorporation of marker nucleotides according to step (1) and, where applicable, according to step (4) is achieved by using dUTP in combination with the four standard deoxynucleoside triphosphates (dNTPs; deoxyadenosine triphosphate, dATP; deoxyguanosine triphosphate, dGTP; deoxythymidine triphosphate, dTTP; deoxycytidine triphosphate, dCTP) in the template-directed polymerase reaction. The ratio of the dUTP to the dTTP concentration in this reaction can be chosen in a wide range in order to control marker nucleotide incorporation probability and, thereby, control the recombination distances. The exact ratio has to be adapted to the discrimination rate between dTTP and dUTP of the polymerase used in the template-directed polymerase reaction as well as to the desired average distance between recombination sites. The discrimination rates between dTTP and dUTP for a few of the aforementioned polymerases are: Taq DNA polymerase (V_{\max}/K_m for the incorporation of dTTP) / (V_{\max}/K_m for the incorporation of dUTP) = 1.2; Klenow DNA polymerase = 1.6; Vent DNA polymerase = 1.4; MMLV reverse transcriptase = 6.3 (*J. Biol. Chem.* 275 (2000) 40266). As an example, when Taq DNA polymerase from *Thermus aquaticus* is used and average distances in the range of 20 to 60 nucleobases are desired, the concentration ratio of dTTP to dUTP should, preferably, be lower than 100,000 and be higher than 0.001. More preferably the ratio should be lower than 1,000 and be higher than 0.1. Most preferably, the concentration ratio of dTTP to dUTP should be in the range of 10.

In another preferred embodiment the nucleic acids used are DNA and 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) is used as the marker nucleotide in

combination with the four standard dNTPs in the template directed polymerase reaction. The marker incorporation probability and, thereby, the distance between recombination sites can be controlled by choosing an appropriate concentration ratio between 8-oxo-dGTP and dGTP. As an example, when Taq DNA polymerase from *Thermus aquaticus* is used and average distances in the range of 20 to 60 nucleobases are desired, the concentration ratio of 8-oxo-dGTP to dGTP in this reaction should preferably be chosen between 100,000 and 10. More preferably, the concentration ratio should be chosen between 10,000 and 100. Most preferably, the concentration ratio should be in the range of 1,000.

In another preferred embodiment marker nucleotides with one of the following modified bases are used in combination with the four standard dNTPs in the template directed polymerase reaction: 3-methyladenine, 7-methyladenine, 3-methylguanine, 7-methylguanine, 7-hydroxyethylguanine, 7-chloroethylguanine, O2-alkylthymine, O2-alkylcytosine, 5-fluorouracil, 2,5-amino-5-formamidopyrimidine, 4,6-diamino-5-formamidopyrimidine, 2,6-diamino-4-hydroxy-5-formamidopyrimidine, 5-hydroxycytosine, 5,6-dihydrothymine, 5-hydroxy-5,6-dihydrothymine, thymine glycol, uracil glycol, isodialuric acid, alloxan, 5,6-dihydrouracil, 5-hydroxy-5,6-dihydrouracil, 5-hydroxyuracil, 5-formyluracil, 5-hydroxymethyluracil, hypoxanthine, 1,N6-ethenoadenine, or 3,N4-ethenocytosine. For the polymerase reaction any enzyme with template directed polynucleotide-polymerization activity can be used which is able to incorporate these marker nucleotides.

In another preferred embodiment the marker strand nucleic acid is DNA, and one, two, three or all four ribonucleoside triphosphates (rNTPs) are used in combination with the four standard dNTPs in the template directed polymerase reaction. The concentration ratio of the rNTP to the corresponding dNTP in this reaction can be used to control the marker incorporation probability and, thereby, the distance between recombination sites. Discrimination ratios (V_{\max}/K_m for the incorporation of dNTP) / (V_{\max}/K_m for the incorporation of rNTP) for Taq DNA polymerase are: dUTP/rUTP = 1,500,000, dCTP/rCTP = 24,000; for Klenow DNA polymerase: dUTP/rUTP = 130,000, dCTP/rCTP = 3,100; for Vent DNA polymerase: dUTP/rUTP = 10,000, dCTP/rCTP = 2,000; and for MMLV reverse transcriptase: dUTP/rUTP = 21,000, dCTP/rCTP = 1,100 (1. Biol. Chem. 275 (2000) 40266). As

an example, when Vent DNA polymerase is used in combination with rCTP as the marker nucleotide, and average distances in the range of 20 to 60 nucleobases are desired, the concentration ratio of rCTP to dCTP should preferably be lower than 10,000 and higher than 1. More preferably, the ratio should be lower than 1,000 and higher than 10. Most preferably the ratio should be in the range of 100.

The formation of double-stranded heteroduplices according to step (2) of the method of the invention is preferably achieved by hybridization of the homologous segments of the source nucleic acid molecules. The term "heteroduplices" means double strands with at least one homologous and at least two heterologous segments. By using a population of nucleic acid sequences with heterologous segments, heteroduplices are formed with a statistical probability which corresponds to the relative frequency of sequence variants in the population. Starting out, for example, from an equimolar mixture of two variants having two heterologous segments, a heteroduplex statistically occurs with every second double-stranded nucleic acid. If the number of variants is markedly higher than the relative frequency of individual variants, heteroduplices are formed almost exclusively.

Hybridization of homologous segments of the source nucleic acids to form heteroduplices is carried out according to methods known to the person skilled in the art. In a preferred embodiment the source nucleic acid molecules are single-stranded and the hybridization is achieved by combining said single strands and adjusting reaction conditions which promote the annealing of homologous nucleic acids, e.g. by lowering of the temperature or adjusting the salt concentration. In another preferred embodiment, the source nucleic acid molecules are double-stranded and the hybridization is achieved by melting the double strands under appropriate conditions, e.g. at temperatures higher than the melting temperature of the double strand, and allow the strands to re-anneal, e.g. by lowering the temperature below the melting temperature of the double strand.

The production of single-stranded breaks at the positions of incorporated marker nucleotides according to step (3) of the invention is preferably achieved by chemical or enzymatic reactions. The term "breaks" means nicks or gaps in a nu-

cleic acid strand that can serve as starting points for a template-directed polymerase reaction.

In a preferred embodiment, the single-stranded break is achieved by removing the marker nucleotide by the action of one or more enzymes leading to a single nucleotide gap and a free 3'-OH residue on the 5' side of said gap, the free 3'-OH being extendable by a polymerase according to step (4) of the method.

In a particularly preferred embodiment, when DNA is the nucleic acid and dUTP is used as marker nucleotide, the uracil base of the incorporated marker uridine residues is separated from the ribose by action of an uracil-DNA glycosylase (UDG, Figures 2 - 4). A large number of different UDGs isolated from various species has been described (Rev. Biochem. Tox. 9 (1988) 69; Mutat. Res. 460 (2000) 165). UDGs are involved in a base-excision pathway initiated by deamination of the DNA base cytosine leading to uracil or by misincorporation of uridine during DNA replication. The use of UDGs in PCR-carry-over-prevention has been described (Gene 93 (1990) 125). UDG from *E. coli* is commercially available in the engineered and in the non-engineered form by various manufacturers. *E. coli* UDG efficiently hydrolyzes uracil from single-stranded or double-stranded DNA, but not from dUTP. The minimal substrate for UDG was found to be pd(UN)p (Biochemistry 30 (1991) 4055). The reaction can be started e.g. by changing the buffer conditions or the temperature or by adding the UDG, and can be stopped, for instance, by changing the buffer conditions or the temperature or by adding an UDG inhibitor. The separation of the uracil bases from DNA containing uridine residues results in apyrimidinic sites (AP sites).

In another particularly preferred embodiment, when DNA is the nucleic acid and 8-oxo-dGTP is used as marker nucleotide, the 8-oxo-guanine base is separated from the ribose using formamidopyrimidine-DNA glycosylases (Fpg) (EMBO J. 6 (1987) 3177). The reaction can be started e.g. by changing the buffer conditions or the temperature or by adding the enzyme and can be stopped, for instance, by changing the buffer conditions or temperature or by adding an inhibitor. In addition to its formamidopyrimidine-glycosylase activity, this protein also has a nicking activity that cleaves via a α,β -elimination both the 5'- and 3'-phosphodiester bonds at an AP site (Biochem. J. 262 (1990) 581). Thus the treatment of a

polynucleotide molecule containing the 8-oxo-GMP residues leads to gaps of a single nucleotide with a phosphate group both at the 5'- and 3'-end.

In another particularly preferred embodiment any other DNA N-glycosylase which detects one of the aforementioned modified bases is employed. *E. coli* alkylbase-DNA glycosylase (alkA gene product, Mol. Gen. Genet. 197 (1984) 368), for example, separates the bases from 3-methyladenosine, 7-methyladenosine, 3-methylguanosine, 7-methylguanosine, 7-hydroxyethylguanosine, 7-chloroethylguanosine, O2-alkylthymidine, O2-alkylcytidine, hypoxanthosine, 1,N6-etheno-adenosine or 3,N4-ethenocytidine. *E. coli* endonuclease III (Biochem. J. 242 (1987) 565), as an alternative, separates the bases from 5-hydroxycytidine, 5,6-dihydrothymidine, 5-hydroxy-5,6-dihydrothymidine, thymidine glycol, uridine-glycol, alloxan, 5,6-dihydrouridine, 5-hydroxy-5,6-dihydrouridine or 5-hydroxy-uridine. Endonuclease III has in addition to its DNA N-glycosylase activity an AP lyase activity which cleaves at the 3'-end bond of an AP site via β -elimination (Nucl. Acid. Res. 16 (1988) 1135). Thus the treatment of a nucleic acid molecule containing the aforementioned substrate residues for endonuclease III leads to nicks with a α,β -unsaturated aldehyde (*trans*-4-hydroxy-2-pentenal-5-phosphate) at the 3'-end and a phosphate group at the 5'-end.

In another particularly preferred embodiment, when DNA is the nucleic acid and one or more rNTPs are used as marker nucleotides, the rNMP residues incorporated in a DNA double strand can be recognized by a ribonuclease H (RNase H, Figure 5). Preferably, RNase H1 from K562 human erythroleukemia cells is used, that cleaves at the 5'-site of an RNA segment in the DNA strand consisting of one or more ribonucleotide residues (J. Biol. Chem. 266 (1991) 6472). This reaction leads to a nick with a 5'-p-rNMP residue at one side and a free 3'-OH group at the other side. Alternatively, other RNases H can be employed, e.g. *E. coli* RNase H or the RNase H activity of reverse transcriptases. The reaction can be started e.g. by changing the buffer conditions or the temperature or by adding the enzyme and can be stopped, for instance, by changing the buffer conditions or temperature or by adding an inhibitor.

In a preferred embodiment the AP site resulting from the action of a DNA N-gly-

donuclease IV (J. Biol. Chem. 252 (1977) 2808) or Exonuclease III (J. Biol. Chem., 239 (1964) 242) can be used for this reaction. The incubation of a polynucleotide molecule containing AP sites with these enzymes leads via hydrolysis to a nick with a 5'-deoxyribosephosphate (dRp) group at one side and a free 3'-OH group at the other side (Nucl. Acid. Res. 18 (1990) 5069).

In a particularly preferred embodiment the 5'-dRp group resulting from the action of a class II AP endonuclease is cleaved by an enzyme showing deoxyribosephosphatase activity (dRpasen). For this reaction, a multitude of enzymes can be employed. For example: E. coli exonuclease I (Nucl. Acid. Res. 20 (1992) 4699), E. coli RecJ protein (Nucl. Acid. Res. 22, 1994, 993); E. coli endonuclease III (Nucl. Acid. Res. 17, 1989, 6269); E. coli formamidopyrimidine-DNA glycosylase (Fpg, J. Biol. Chem. 267, 1992, 14429); E. coli endonuclease VIII (J. Biol. Chem. 272, 1997, 32230); T4 endonuclease V (Biochemistry 32, 1993, 8284); T4 DNA ligase (J. Biol. Chem. 273, 1998, 7888); T7 DNA ligase (J. Biol. Chem. 273, 1998, 7888) or DNA polymerase I, T7 DNA polymerase and MMLV reverse transcriptase (J. Biol. Chem. 275, 2000, 12509).

In another preferred embodiment the AP site resulting from the action of a DNA N-glycosylase is cleaved by a class I AP endonuclease (Figure 3). For this reaction, E. coli endonuclease III (Biochem. J. 242, 1987, 565-573) or T4 endonuclease V (Mutat. Res. 459, 2000, 43-53) can be employed. The incubation of a polynucleotide molecule containing AP sites with these enzymes leads via β -elimination to a nick with a α,β -unsaturated aldehyde (*trans*-4-hydroxy-2-pentenal-5-phosphate) at the 3'-end and a phosphate group at the 5'-end (FEBS Lett. 178, 1984, 223; Nucl. Acid. Res. 16, 1988, 1135). The 3'-aldehyde has to be removed by a class II AP endonuclease such as exonuclease III or endonuclease IV (Biochem. J. 242, 1987, 565) resulting in a free 3'-OH group.

In a preferred embodiment the AP site resulting from the action of a DNA N-glycosylase is cleaved by an AP lyase which cleaves at the AP site via a α,β -elimination (Figure 4). E. coli endonuclease VIII (J. Biol. Chem. 272, 1997, 32230) and E. coli formamidopyrimidine-DNA glycosylase (Fpg, J. Biol. Chem. 267, 1992, 14429) can be employed for this purpose. The incubation of a DNA double strand containing AP sites with these enzymes leads to one of one nucleotide with a 3'

phosphate residue at one side of the gap and a 5'-phosphate residue at the other side of the gap. Afterwards, the 3'-phosphate group is removed by a class II AP endonuclease, as for example Exonuclease III or Endonuclease IV (J. Biol. Chem. 258, 1983, 15198) or by T4 polynucleotide kinase (Biochemistry 16, 1977, 5120) resulting in a free 3'-OH group.

In another preferred embodiment the marker strand consisting of DNA and containing rNMP residues is cleaved by alkaline hydrolysis. This reaction leads to a nick with a 2'- or 3'-rNMP at the 3'-end and an OH group at the 5'-end. The reaction can be started and stopped by changing the pH.

In another preferred embodiment the 2'- or 3'-rNMP at the 3'-end of a nick resulting from the alkaline hydrolysis of a DNA polynucleotide containing rNMPs is removed by a class II AP endonuclease. Preferably, Exonuclease III or Endonuclease IV are used, resulting in a free 3'-OH group.

According to step (4), the free 3'-OH group at a nick or gap resulting from one or more of the aforementioned reactions is extended with a template directed polymerase reaction with or without the incorporation of additional marker nucleotides.

In a preferred embodiment the remaining part of the marker strand 3' of the single strand break, in particular strands containing a 5'-dRp group resulting from the action of a class II AP endonuclease, are bound with a surplus of the corresponding complementary strands and are thereby removed from the template strand. Then, any kind of polymerase can be employed to extend the 3'-OH group by template-directed polymerization.

In another preferred embodiment the remaining part of the marker strand 3' of the single strand break is removed from the template strand by employing a polymerase showing strong strand displacement properties. Preferably, Vent DNA polymerase or Klenow DNA polymerase are employed for this purpose.

In another preferred embodiment the remaining part of the marker strand 3' of the single strand break is removed from the template strand by a 5'-exonuclease

activity. For this purpose, any polymerase showing a 5'-exonuclease activity can be employed. Preferably, Taq DNA polymerase or Tth DNA polymerase are used. Alternatively, 5'-3' exonucleases can be used in combination with any polymerase. Then, preferably, Lambda Exonuclease (Gene Amplification and Analysis 2,1981, 135) or T7 Exonuclease (Nucl. Acid. Res. 5, 1978, 4245) are used.

Embodiment (B) of the invention relates to a kit containing instructions for carrying out the method embodiment (A) of the invention. Preferably, said kit contains the following components:

- (i) marker nucleotides for incorporation in the polynucleotide molecules;
- (ii) agents permitting the single-stranded breaks at the incorporated marker nucleotides; and
- (iii) buffers for carrying out the incorporation of the marker nucleotides and producing the single-stranded breaks.

The kit may contain further components, e.g. one or more of the following:

- (iv) a buffer for producing double-stranded polynucleotides;
- (v) agents permitting the template-directed polymerization of a polynucleotide strand starting from the single-stranded break; and
- (vi) buffer for carrying out the polymerization reaction.

The invention is further explained by the following examples, which are, however, not to be construed to limit the invention.

Examples

Example 1 : Generating single recombination events per gene that are randomly distributed

1. Provide partially homologous and heterologous genes to be recombined. Amplify the genes by PCR introducing an *Eco* RI restriction site at the one end and a *Hind* III restriction site at the other end.
2. Incubate 1 µg of each PCR product and 1 µg of pUC18 vector with 1 U *Eco* RI (e.g. NEB) and 1 U *Hind* III (e.g. NEB) in *Eco* RI reaction buffer (100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM MgCl₂, 0.025 % (v/v) Triton® X-100)

for 2 h at 37 °C. Heat inactivate the enzymes for 20 min at 65 °C. Purify the cleavage products e.g. with QiaQuick (Qiagen).

3. Ligate the PCR products into the pUC18 vector using 200 fmol vector, 600 fmol insert, 1 µl of 10X Ligation Buffer (500 mM Tris-HCl, pH 7.5; 100 mM MgCl₂; 100 mM DTT; 10 mM ATP, 250 µg/ml BSA), 5 Weiss Unit of T4 DNA ligase (e.g. NEB) ad 10 µl aqua dest. Incubate 1 h at room temperature and heat inactivate the enzyme for 10 min at 65 °C. Transform *E. coli* XL1-Blue with the ligated vector, e.g. by electroporation. Make plasmid preparations from positive clones using e.g. Qiagen Mini Plasmid Prep Kits.

4. Amplify the inserted genes with a PCR using the primers:

pUC-left: 5'-CCAGTCACGACGTTGTAAAACG-3' (SEQ ID NO:1)

pUC-right: 5'-TAACAATTTACACAGGAAACAGC-3' (SEQ ID NO:2)

by mixing 10 µl 10X PCR buffer (200 mM Tris-HCl, pH 8.75; 100 mM KCl; 100 mM (NH₄)₂ SO₄; 20 mM MgCl₂; 1 % (v/v) Triton® X-100; 1 mg/ml BSA), 10 fmol template vector, 100 pmol pUC-left, 100 pmol pUC-right, 200 µM dNTPs, 2 U Pfu DNA polymerase (e.g. Stratagene) ad 100 µl aqua dest. and using the following cycler protocol: 1' 94 °C; 30 cycles consisting of 1' 94 °C, 1' 50 °C, 1.5' 72 °C; 2' 72 °C. Purify the PCR products, e.g. with QiaQuick®.

5. Make a set of asymmetric PCRs with the mixed PCR-products as templates varying the added dUTP concentration (e.g. 0.2 µM; 1 µM; 5 µM; 25 µM; 100 µM dUTP) by mixing 10 µl 10X PCR buffer (100 mM Tris-HCl, pH 8.3; 500 mM KCl; 15 mM MgCl₂; 0.01 % (w/v) gelatin), 1 pmol template DNA, 100 pmol pUC-left, 100 pmol blocked pUC-right (3'-NH₂ modification), 200 µM dNTPs, any of the above mentioned dUTP concentrations, 2 U Taq DNA polymerase (e.g. Applied Biosystems) ad 100 µl aqua dest., and using the following cycler protocol: 1' 94 °C; 30 cycles consisting of 1' 94 °C, 1' 50 °C, 1.5' 72 °C. Purify the PCR products, e.g. with QiaQuick® (Qiagen) and pool the PCR-products as marker strands.

Make an asymmetric PCR with the mixed PCR-products as template (anti-

500 mM KCl; 15 mM MgCl₂; 0.01 % (w/v) gelatin), 1 pmol template DNA, 100 pmol blocked pUC-left (3'-NH₂ modification), 100 pmol pUC-right, 200 µM dNTPs, 2 U Taq DNA polymerase (e.g. Applied Biosystems) ad 100 µl aqua dest., and using the following cycler protocol: 1' 94 °C; 30 cycles consisting of 1' 94 °C, 1' 50 °C, 1.5' 72 °C. Purify the PCR products, e.g. with QiaQuick® (Qiagen) and pool the PCR-products as template strands.

6. Anneal 2 pmol of sense strand (with incorporated dU's) and 2 pmol of anti-sense strand in 100 mM NaCl (2' 95 °C, 95 °C -> 50 °C with 0,04 °C/s). Purify the annealed double stranded DNA, e.g. with QiaQuick®-Kit
7. Incubate 2 pmol of the annealed double stranded DNA with 1 U UDG (e.g. NEB) and 2 U Endonuclease IV (e.g. Epicentre) 1h at 37 °C in 20 µl UDG-Puffer (20 mM Tris-HCl, pH 8.0; 1 mM EDTA; 1 mM DTT). Add 80 µl of Vent-buffer (20 mM Tris-HCl, pH 8.8; 10 mM KCl; 10 mM (NH₄)₂SO₄; 2 mM MgSO₄; 0.1 % (v/v) Triton® X-100), 200 µM dNTPs and 2 U Vent(exo-) DNA polymerase (NEB). Incubate 5 min at 72 °C. Purify the DNA with QiaQuick® (Qiagen).
8. Incubate the product and 1 µg of pUC18 vector each with 1 U *Eco* RI (e.g. NEB) and 1 U *Hind* III (e.g. NEB) in *Eco* RI reaction buffer (100 mM Tris-HCl, pH 7.5; 50 mM NaCl; 10 mM MgCl₂; 0.025 % (v/v) Triton® X-100) for 2 h at 37 °C. Heat inactivate the enzymes for 20 min at 65 °C. Purify the cleavage products e.g. with QiaQuick®-Kit.).
9. Ligate the product into the pUC18 vector using: 200 fmol vector, 600 fmol insert, 1 µl of 10X Ligation Buffer (500 mM Tris-HCl, pH 7.5; 100 mM MgCl₂; 100 mM DTT; 10 mM ATP, 250 µg/ml BSA), 5 Weiss Unit of T4 DNA ligase (e.g. NEB) ad 10 µl aqua dest. Incubate 1 h at room temperature and heat inactivate the enzyme for 10 min at 65 °C. Transform *E. coli* XL1-Blue with the ligated vector.

For steps 1. to 4. see Example 1.

5. Make an asymmetric PCR with the mixed PCR-products as template by mixing 10 µl 10X PCR buffer (100 mM Tris-HCl, pH 8.3; 500 mM KCl; 15 mM MgCl₂; 0.01 % (w/v) gelatin), 1 pmol template DNA, 100 pmol pUC-left, 100 pmol locked pUC-right (3'-NH₂ modification), 200 µM dNTPs, 2 µM dUTP, 2 U Taq DNA polymerase (e.g. Applied Biosystems) ad 100 µl aqua dest., and using the following cycler protocol: 1' 94 °C; 30 cycles consisting of 1' 94 °C, 1' 50 °C, 1.5' 72 °C. Purify the PCR products, e.g. with QiaQuick[®] (Qiagen) as marker strands.

Make an asymmetric PCR with the mixed PCR-products as template by mixing 10 µl 10X PCR buffer (100 mM Tris-HCl, pH 8.3; 500 mM KCl; 15 mM MgCl₂; 0.01 % (w/v) gelatin), 1 pmol template DNA, 100 pmol blocked pUC-left (3'-NH₂ modification), 100 pmol pUC-right, 200 µM dNTPs, 2 U Taq DNA polymerase (e.g. Applied Biosystems) ad 100 µl aqua dest., and using the following cycler protocol: 1' 94 °C; 30 cycles consisting of 1' 94 °C, 1' 50 °C, 1.5' 72 °C. Purify the PCR products, e.g. with QiaQuick[®] (Qiagen) as template strands.

6. Anneal 2 pmol of marker strand (with incorporated dU's) and 2 pmol of template strand in 100 mM NaCl (2' 95 °C, 95 °C -> 50 °C with 0,04 °C/s). Purify the annealed double stranded DNA, e.g. with QiaQuick[®]-Kit (Qiagen).
7. Incubate 2 pmol of the annealed double stranded DNA with 1 U UDG (e.g. NEB) and 2 U Endonuclease IV (e.g. Epicentre) 1h at 37 °C in 20 µl UDG-Puffer (20 mM Tris-HCl, pH 8.0; 1 mM EDTA; 1 mM DTT). Add 2 U of UGI (Uracil Glycosylase Inhibitor, e.g. NEB). Add 80 µl of Vent-buffer (20 mM Tris-HCl, pH 8.8; 10 mM KCl; 10 mM (NH₄)₂SO₄; 2 mM MgSO₄; 0.1 % (v/v) Triton[®] X-100), 200 µM dNTPs, 2 µM dUTP and 2 U Vent(exo-) DNA polymerase (NEB). Incubate 5 min at 72 °C. Purify the DNA (e.g. with QiaQuick[®]).
8. Reanneal the various strands in 100 mM NaCl (2' 95 °C, 95 °C -> 50 °C with 0,04 °C/s).

9. Repeat steps 7 and 8 several times (the number of cycles should equal the length of gene in bp / 100).
10. Incubate the product and 1 µg of pUC18 vector each with 1 U *Eco* RI (e.g. NEB) and 1 U *Hind* III (e.g. NEB) in *Eco* RI reaction buffer (100 mM Tris-HCl, pH 7.5; 50 mM NaCl; 10 mM MgCl₂; 0.025 % (v/v) Triton® X-100) for 2 h at 37 °C. Heat inactivate the enzymes for 20 min at 65 °C. Purify the cleavage products e.g. with QiaQuick®-Kit.
11. Ligate the product into the pUC18 vector using: 200 fmol vector, 600 fmol insert, 1 µl of 10X Ligation Buffer (500 mM Tris-HCl, pH 7.5; 100 mM MgCl₂; 100 mM DTT; 10 mM ATP, 250 µg/ml BSA), 5 Weiss Unit of T4 DNA ligase (e.g. NEB) ad 10 µl aqua dest. Incubate 1 h at room temperature and heat inactivate the enzyme for 10 min at 65 °C. Transform *E. coli* XL1-Blue with the ligated vector.

Example 3: Generating randomly recombined subtilisin genes

Four partially homologous and partially heterologous subtilisin genes were recombined according to the method of the invention as follows. The four genes were the wild type gene and three mutants, variant 15, variant 21, and variant 22, from the gene *aprE* coding for Subtilisin E from *B. subtilis* (see Figure 7 and SEQ ID NO:5 showing the amino acid sequence of the *aprE* encoded subtilisin E - protein).

1. Each of the four partially homologous and partially heterologous genes was PCR-amplified using the primers:

PrimerHL: 5'-CGTTGCATATGTGGAAGAAGATC-3' (SEQ ID NO:3)

PrimerHR: 5'-GAAGCAGGTATGGAGGAAC-3' (SEQ ID NO:4)

PCR was performed by mixing 10 µl 10x PCR buffer (200 mM Tris-HCl, pH 8.8; 100 mM KCl; 100 mM (NH₄)₂SO₄; 25 mM MgSO₄; 1 % (v/v) Triton® X-100; 1 mg/ml BSA), 10 fmol template, 100 pmol PrimerHL, 100 pmol PrimerHR, 200 µM dNTPs, 2.5 U Taq DNA polymerase (MBI Fermentas), ad 100 µl aqua dest, using the following thermal cycler protocol: 1' 94 °C; 25 cycles consisting of 1' 94 °C, 1' 55 °C, 1' 5' 72 °C, 2' 72 °C. PCR products

were purified with the QiaQuick® PCR purification kit (Qiagen, Hilden, Germany).

2. In a second PCR, each of the four genes was PCR-amplified under incorporation of the marker nucleotide using the same primers as in step 1. PCR was performed by mixing 200 µM of a dNTP mix where dTTP is reduced and replenished by dUTP to result in a ratio of dUTP/dTTP of 1:40, with 10 µl 10x PCR buffer (750 mM Tris-HCl, pH 8.8; 200 mM (NH₄)₂SO₄; 25 mM MgCl₂; 0.1 % (v/v) Tween® 20); 2.5 U Taq DNA polymerase (MBI Fermentas) and 100 µl aqua dest, using the following thermal cycler protocol: 1' 94 °C; 25 cycles consisting of 1' 94 °C, 1' 52 °C, 1.5' 72 °C. PCR products were purified with the QiaQuick® PCR purification kit (Qiagen, Hilden, Germany).
3. A 1:1 mixture of marker-incorporated to marker-free polynucleotides was made by mixing 0.5 µg (approx. 1 pmol) of each PCR product of step 2 (marker incorporated) and 0.5 µg (approx. 1 pmol) of each PCR product of step 1 (marker-free) in 100 mM NaCl. Produce heteroduplex molecules by heating for 2' at 94 °C, and cooling down to 50 °C with a rate of 0.04 °C/s). Analogously, 1:3 and 1:9 mixtures of marker-incorporated to marker-free polynucleotides were made by mixing corresponding amounts of PCR products from step 2 and 1, and producing heteroduplex molecules by the same protocol.
4. 2 µg (approx. 3.8 pmol) of each of the heteroduplex molecule mixtures was incubated for 30 min at 37 °C with 1 U UDG (NEB) in 20 µl 1x UDG-buffer (20 mM Tris-HCl, pH 8.0; 1 mM EDTA; 1 mM DTT). 2 U Endonuclease IV (Epicentre) were added, the reaction volume was increased to 20 µl with 1x UDG-buffer, and the mixtures were incubated for additional 30 min at 37 °C. Then, 80 µl Taq-buffer (750 mM Tris-HCl, pH 8.8; 200 mM (NH₄)₂SO₄; 0.1 % Tween 20), 200 µM dNTPs, and 2.5 U Taq DNA Polymerase (MBI Fermentas) were added, and the mixtures were incubated for additional 5 min at 72°C. Products were purified with the QiaQuick® PCR purification kit (Qiagen, Hilden, Germany).

5. Polynucleotides were resuspended in 100 mM NaCl and again heteroduplex

molecules were produced by melting strands through heating for 2' at 94 °C, and cooling down to 50 °C with a rate of 0.04 °C/s).

6. Steps 4 and 5 were repeated two times.
7. Finally, in order to separate heteroduplex strands, 20 pmol of PrimerML and PrimerMR were added to each mixture, and 3 cycles PCR using the cycler protocol: 1' 94 °C, 1' 52 °C, 1.5' 72 °C were performed. Recombined polynucleotides were purified using the QiaQuick® PCR purification kit (Qiagen, Hilden, Germany).
8. Recombined polynucleotides were then ligated into the vector pBVP43 (see Figure 7) behind the P43 promotor with the vector being constructed as follows: The pMB1 origin from pUC19 (ATCC 37254) was PCR amplified (positions 763 - 1601) and introduced into the PvuII site of pUB110 (ATCC 37015). The fragment between SapI and BglII was removed from this vector. Then, an insert containing the P43 promoter from the *cdd* gene of *B. subtilis*, the signal sequence and the terminator from the subtilisin E gene of *B. subtilis*, as well as a short multiple cloning site between the signal sequence and the terminator was introduced into the unique SphI site, resulting in the vector pBVP43empty. The wild type subtilisin E gene (coding for the protein of SEQ ID NO:5 and being derivable from the genome of *Bacillus subtilis* strain 168 (DSM #402)) without the signal sequence as well as any other subtilisin variant was introduced in frame with the signal sequence into the multiple cloning site resulting in the vector pBVP43.
9. Recombined polynucleotides were then ligated into the vector pBVP43 (see Figure 7) behind the P43 promotor. Ligation was done using 300 fmol vector, 1500 fmol insert, 2 µl of 10x Ligation buffer (500 mM Tris-HCl, pH 7.5; 100 mM MgCl₂; 100 mM DTT; 10 mM ATP, 250 µg/ml BSA), 5 Weiss Units of T4 DNA ligase (MBI Fermentas), ad 20 µl aqua dest, by incubation for 2 h at room temperature, followed by heat inactivation for 10 min at 65 °C, and ethanol precipitation. The ligation mixture was then transformed into electrocompetent *E. coli* XL1-Blue.

10. Isolated clones were sequenced in order to determine the number of recombinants and the frequency of recombination events.

Results from the sequence analysis of a representative set of clones are shown in Figure 8. which shows a comparison of amino acid residues of the starting material of the wild type subtilisin and three mutants thereof and those of the recombinants obtained by the use of the method of this invention. The amino acids are abbreviated as shown in Table I below.

Overall, 17 out of 26 clones were recombined corresponding to 65 % recombinants. The average number of recombination events per gene over all clones was approximately 1.2.

As shown in Figure 9, the ratio of marker-free to marker-incorporated PCR products of 1:1 and 1:3 showed approximately 75 % recombinants (Figure 9B); the recombinants resulting of the 1:3 mixture had on average 1.50 recombination events in comparison to the 1:1 mixture (Figure 9A).

Table I: Amino acid abbreviations

Abbreviations		Amino acid
A	Ala	Alanin
C	Cys	Cysteine
D	Asp	Aspartic acid
E	Glu	Glutamic acid
F	Phe	Phenylalanine
G	Gly	Glycine
H	His	Histidine
I	Ile	Isoleucine
K	Lys	Lysine
L	Leu	Leucine
M	Met	Methionine
N	Asn	Asparagine
P	Pro	Proline
Q	Gln	Glutamine
R	Arg	Arginine
S	Ser	Serine
T	Thr	Threonine
V	Val	Valine
W	Trp	Tryptophane
Y	Tyr	Tyrosine

Claims

1. A method for the production of polynucleotide molecules with modified properties, comprising the following steps:

- (1) providing a population of source nucleic acid molecules, the individual nucleic acid molecules of said population having homologous and heterologous segments and having at least one marker nucleotide incorporated within its nucleic acid sequence;
- (2) forming double-stranded polynucleotide molecules of the population of source nucleic acid molecules provided according to step (1) comprising double strands with heterologous segments (heteroduplices);
- (3) producing single-stranded breaks at the incorporated marker nucleotides of the double-stranded heteroduplices produced according to step (2); and
- (4) performing template-directed single-strand synthesis, with or without incorporation of marker nucleotides starting from single-stranded breaks produced according to step (3).

2. The method of claim 1, wherein

- (i) more than one cycle, preferably at least two cycles, more preferably at least ten and most preferably at least twenty cycles, comprising the aforementioned steps (2) to (4) are performed; and/or
- (ii) in all cycles but the last, step (4) is carried out with the incorporation of new marker nucleotides; and/or
- (iii) steps (3) and (4) are carried out subsequently or contemporaneously.

3. The method of claim 1 or 2, wherein

- (i) homologous segments have a length of at least 5, preferably of at least 10 and more preferably of at least 20 nucleotides and/or are not longer than 5,000 nucleotides, preferably not longer than 2,000 nucleotides, more preferably not longer than 1,000 nucleotides; and/or
- (ii) the homologous segments are flanked by heterologous segments.

4. The method of any one of claims 1 to 3, wherein

- (i) the incorporation of marker nucleotides into the nucleic acid molecules according to step (1) is achieved by using a template-directed polymerase reaction or by chemical synthesis of oligonucleotides; and/or
- (ii) the production of double-stranded heteroduplex polynucleotides according to step (2) is achieved by hybridization of the homologous segments of complementary polynucleotides; and/or
- (iii) the single-stranded breaks at the positions of the incorporated marker nucleotides of step (3) are nicks or gaps which are achieved by using enzymatic reactions; and/or
- (iv) the template-directed single-strand synthesis of step (4) utilizes a polymerase.

5. The method of claim 1 or 4, wherein more than one cycle comprising steps (2) to (4) is performed and the average distance between the starting points of the template-directed synthesis according to step (4) in each of two consecutive cycles is controlled by adjusting the probability of incorporating marker nucleotides in step (4) of the first of the two consecutive cycles.

6. The method according to claim 5, wherein the probability of incorporating marker nucleotides is controlled by adjusting the ratio of concentrations of marker nucleotides to standard nucleotides; and/or wherein the probability of incorporating marker nucleotides is preferably lower than one and higher than the reciprocal of the source nucleic acid length in base pairs; and/or wherein the probability of incorporating marker nucleotides is altered from cycle to cycle.

7. The method of any one of claims 4 to 6, wherein the nucleic acid molecules are DNA molecules and in the template-directed polymerase reaction deoxyuridine triphosphate (dUTP) is utilized as a marker nucleotide in combination with the four standard deoxynucleoside triphosphates; and/or the uracil base of the incorporated marker uridine residues is separated from the ribose using an uracil-DNA glycosylase.

8. The method of any one of claims 4 to 6, wherein the nucleic acid molecules are DNA molecules and in the template directed polymerase reaction 8-oxo-dGTP is utilized as a marker nucleotide in

combination with the four standard deoxynucleoside triphosphates; and/or the 8-oxo-guanine base of the incorporated 8-oxo-GMP residues is separated from the ribose using formamidopyrimidine-DNA glycosylases.

9. The method of any one of claims 4 to 6, wherein the nucleic acid molecules are DNA molecules and in the template directed polymerase reaction marker nucleotides with the following modified bases are used in combination with the four standard dNTPs: 3-methyladenine, 7-methyladenine, 3-methylguanine, 7-methylguanine, 7-hydroxyethylguanine, 7-chloroethylguanine, O2-alkylthymine, O2-alkylcytosine, 5-fluorouracil, 2,5-amino-5-formamidopyrimidine, 4,6-diamino-5-formamidopyrimidine, 2,6-diamino-4-hydroxy-5-formamidopyrimidine, 5-hydroxycytosine, 5,6-dihydrothymine, 5-hydroxy-5,6-dihydrothymine, thymine glycol, uracil glycol, isodialuric acid, alloxan, 5,6-dihydrouracil, 5-hydroxy-5,6-dihydrouracil, 5-hydroxyuracil, 5-formyluracil, 5-hydroxymethyluracil, hypoxanthine, 1,N6-ethenoadenine or 3,N4-ethenocytosine; and/or a DNA N-glycosylase which detects one of the aforementioned modified base, preferably *E.coli* endonuclease III or alkylbase DNA glycosylase, is utilized.

10. The method of any one of claims 4 to 6, wherein the nucleic acid molecules are DNA molecules and in the template directed polymerase reaction one, two, three or all four ribonucleoside triphosphates (rNTPs) are utilized as marker nucleotides in combination with the four standard dNTPs in the template directed polymerase reaction; and/or, the rNMP residues incorporated in the DNA polynucleotide are recognized by a specific ribonuclease H, preferably by human RNase H1.

11. The method of any one of claims 4 to 6, wherein the nucleic acid molecules are DNA molecules, any or all of the four ribonucleoside monophosphates (rNMPs) are used as marker nucleotides, and the marker strand is cleaved by alkaline hydrolysis at the rNMP residues, and/or the 2'- or 3'-rNMP at the 3'-end of a nick resulting from the alkaline hydrolysis is removed by a class II AP endonuclease, preferably by Exonuclease III or Endonuclease IV.

12. The method of any one of claims 4 to 11, wherein in step (4) the 3'OH-group of the nucleic acid molecule resulting from the enzymatic reaction is extended with a tem-

plate directed polymerase reaction with or without the incorporation of additional marker nucleotides, preferably

- (i) strands containing 5'-dRp group resulting from the action of a class II AP endonuclease are bound with a surplus of the corresponding template strands and the 3'-group is extended with a template directed polymerase; and/or
- (ii) the 3'OH-group of the nick is template directed extended with a polymerase showing strong strand displacement properties; and/or
- (iii) the 3'OH-group of the nick or gap is extended by a template directed polymerase showing a 5'3'-exonuclease activity or with other template directed polymerases in combination with an additional 5'3'-exonuclease.

13. The method of any one of claims 1 to 6, wherein the template strands in step (4) at which the template-directed single-strand synthesis takes place are RNA molecules, whereby an RNA-dependent DNA polymerase, preferably AMV reverse transcriptase from the avian myeloblastosis virus, HIV reverse transcriptase from the human immunodeficiency virus or MMLV reverse transcriptase from the Moloney murine leukemia virus are used for the template-directed single-strand synthesis.

14. A kit for carrying out the method as defined in any one of claims 1 to 13, preferably said kit containing of the following components:

- (i) marker nucleotides for incorporation in the polynucleotide molecules;
- (ii) agents permitting the single-stranded breaks at the incorporated marker nucleotides; and
- (iii) buffers for carrying out the incorporation of the marker nucleotides and producing the single-stranded breaks at these sites.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

Clones	Mutations
wt	
22	E160D Q209R T239K E262A Y323H
21	S115P E160G Q209R I217V E262A Y323H
15	N149S E160D Q209R S251G E262K G263D M305V Y323H D354V
Recombinants	
311	1:1 E160G Q209R I217V E262A M305V Y323H D354V
312	1:1 S115P E160G Q209R T239K E262A Y323H
313	1:1 N149S E160D Q209R S251G E262K G263D M305V Y323H D354V
314	1:1 Q209R S251G E262K G263D M305V Y323H D354V
315	1:1 E160D Q209R T239K E262A Y323H
316	1:1 N149S E160D Q209R S251G E262K G263D Y323H
317	1:1 E160G Q209R I217V E262K G263D
318	1:1 E160D Q209R T239K E262K Y323H
331	1:3 N149S E160D Q209R S251G E262K G263D M305V Y323H D354V
332	1:3 T239K
333	1:3 N149S E160D Q209R T239K E262A Y323H D354V
334	1:3 S115P
335	1:3 Q209R E262A Y323H D354V
336	1:3 E160D Q209R T239K E262A Y323H
337	1:3 E160G Q209R E262A Y323H
338	1:3 N149S E160D Q209R S251G E262K G263D M305V D354V
391	1:9 E160D Q209R T239K
392	1:9
393	1:9 E160D
394	1:9 S115P E160G Q209R I217V E262A Y323H
395	1:9
396	1:9 E160D Q209R E262A
397	1:9 N149S E160D Q209R S251G E262A Y323H
398	1:9 E160D
399	1:9 E160D Q209R E262A Y323H
400	1:9 Q209R S251G E262K G263D M305V Y323H D354V

Fig. 8




Fig. 9

SEQUENCE LISTING

<110> DIREVO Biotech AG

<120> Method for the Production of Nucleic Acids Consisting
of Stochastically Combined Parts of Source Nucleic
Acids

<130> 021880wo/JH/BM/ml

<140>

<141>

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer
pUC-Left

<400> 1

ccagtcacga cggttgtaaaa cg

22

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer
pUC-Right

<400> 2

taacaatttc acacaggaaa cagc

24

<210> 3

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PrimerHL

<400> 3

cggtgcatat gtggaagaag atc

23

<210> 4

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PrimerHR

<400> 4

<210> 5

<211> 275

<212> PRT

<213> Bacillus subtilis

<400> 5

Ala Gln Ser Val Pro Tyr Gly Ile Ser Gln Ile Lys Ala Pro Ala Leu
 1 5 10 15

His Ser Gln Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp
 20 25 30

Ser Gly Ile Asp Ser Ser His Pro Asp Leu Asn Val Arg Gly Gly Ala
 35 40 45

Ser Phe Val Pro Ser Glu Thr Asn Pro Tyr Gln Asp Gly Ser Ser His
 50 55 60

Gly Thr His Val Ala Gly Thr Ile Ala Ala Leu Asn Asn Ser Ile Gly
 65 70 75 80

Val Leu Gly Val Ser Pro Ser Ala Ser Leu Tyr Ala Val Lys Val Leu
 85 90 95

Asp Ser Thr Gly Ser Gly Gln Tyr Ser Trp Ile Ile Asn Gly Ile Glu
 100 105 110

Trp Ala Ile Ser Asn Asn Met Asp Val Ile Asn Met Ser Leu Gly Gly
 115 120 125

Pro Thr Gly Ser Thr Ala Leu Lys Thr Val Val Asp Lys Ala Val Ser
 130 135 140

Ser Gly Ile Val Val Ala Ala Ala Gly Asn Glu Gly Ser Ser Gly
 145 150 155 160

Ser Thr Ser Thr Val Gly Tyr Pro Ala Lys Tyr Pro Ser Thr Ile Ala
 165 170 175

Val Gly Ala Val Asn Ser Ser Asn Gln Arg Ala Ser Phe Ser Ser Ala
 180 185 190

Gly Ser Glu Leu Asp Val Met Ala Pro Gly Val Ser Ile Gln Ser Thr
 195 200 205

Leu Pro Gly Gly Thr Tyr Gly Ala Tyr Asn Gly Thr Ser Met Ala Thr
 210 215 220

Pro His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Thr
 225 230 235 240

Trp Thr Asn Ala Gln Val Arg Asp Arg Leu Glu Ser Thr Ala Thr Tyr
 245 250 255

Leu Gly Asn Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Gln Ala
 260 265 270

Ala Ala Gln
 275

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 February 2003 (13.02.2003)

PCT

(10) International Publication Number
WO 2003/012100 A3

(51) International Patent Classification⁷: **C12N 15/10,**
C12Q 1/68

(21) International Application Number:
PCT/EP2002/008122

(22) International Filing Date: 20 July 2002 (20.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01118416.5 31 July 2001 (31.07.2001) EP

(71) Applicant (for all designated States except US): **DIREVO BIOTECH AG** [DE/DE]; Nattermannallee 1, 50829 Köln (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KOLTERMANN, Andre** [DE/DE]; c/o Direvo Biotech AG, Nattermannallee

1, 50829 Köln (DE). **KETTLING, Ulrich** [DE/DE]; c/o Direvo Biotech AG, Nattermannallee 1, 50829 Köln (DE). **GREINER-STÖFFELE, Thomas** [DE/DE]; Untere Eichstädtstrasse 22, 04299 Leipzig (DE). **SPANGENBERG, Oliver** [DE/DE]; c/o DIREVO BIOTECH AG, Nattermannallee 1, 50829 Köln (DE).


(74) Agents: **HELBING, Jörg** et al.; Von Kreisler Selting Werner, Postfach 10 22 41, 50462 Köln (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS



(57) Abstract: The present invention relates to a method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids as well as to a kit containing instructions for carrying out said method.



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

(88) Date of publication of the international search report:

11 March 2004

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/08122

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/10 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 34835 A (DIREVO BIOTECH AG ;MAX PLANCK GESELLSCHAFT (DE)) 17 May 2001 (2001-05-17) cited in the application	14
Y	the whole document	1-13
Y	WO 01 29212 A (COCO WAYNE M ;ARENSDORF JOSEPH J (US); ENCHIRA BIOTECHNOLOGY CORP) 26 April 2001 (2001-04-26) page 7, line 12 - line 15	1-7, 10-13
	--- -/-- ---	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

11 December 2002

Date of mailing of the international search report

15/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ulbrecht, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/08122

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KORKAN H. E. ET AL.: "DNA glycosylases in the base excision repair of DNA" BIOCHEMICAL JOURNAL, vol. 325, 1997, pages 1-16, XP001022967 page 1, right-hand column, line 2 -page 2, right-hand column, line 1 page 11, right-hand column, paragraph 2 figures 2,3 abstract ---	1-13
A	WO 93 18175 A (LIFE TECHNOLOGIES INC) 16 September 1993 (1993-09-16) page 9, line 24 -page 10, line 22 ---	1,4, 9-11,14
A	WO 01 29211 A (DARZINS ALDIS ;HEKTOR HANS J (US); COCO WAYNE M (US); CRIST MICHAEL) 26 April 2001 (2001-04-26) cited in the application page 7, line 24 -page 12, line 16 page 39, line 22 -page 40, line 2 page 45, line 9 -page 45, line 17 claims 5,7,8,31,246,249,315 ---	1-14
E	WO 01 64864 A (COX ANTHONY ;MAXYGEN INC (US); CARR BRIAN (US); NESS JON E (US); A) 7 September 2001 (2001-09-07) page 11, line 15 -page 16, line 11 page 21, line 1 -page 28, line 10 page 41, line 10 -page 50, line 9 page 136, line 28 -page 137, line 4 claims 30-32,41 figure 5 -----	1-7,10, 12-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/08122

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0134835	A	17-05-2001	DE	19953854 A1	28-06-2001
			AU	1520101 A	06-06-2001
			WO	0134835 A2	17-05-2001
			EP	1230390 A2	14-08-2002
WO 0129212	A	26-04-2001	AU	1098001 A	30-04-2001
			AU	2117301 A	30-04-2001
			WO	0129211 A2	26-04-2001
			WO	0129212 A1	26-04-2001
WO 9318175	A	16-09-1993	WO	9318175 A1	16-09-1993
WO 0129211	A	26-04-2001	AU	1098001 A	30-04-2001
			AU	2117301 A	30-04-2001
			WO	0129211 A2	26-04-2001
			WO	0129212 A1	26-04-2001
WO 0164864	A	07-09-2001	AU	4193901 A	12-09-2001
			WO	0164864 A2	07-09-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.